{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Stott KE"],"funding":["National Institute for Health Research (NIHR)","Wellcome Trust"],"pagination":["ofaf190"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12015468"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(4)"],"pubmed_abstract":["<h4>Background</h4>Host immune responses to HIV-associated cryptococcal meningitis are critical in disease outcome. Their interaction with antifungal drug exposure is poorly understood. This study explored associations between immune biomarkers, antifungal drug exposure, and clinical outcomes in HIV-associated cryptococcal meningitis.<h4>Methods</h4>We analyzed serial plasma and cerebrospinal fluid immune biomarkers from 64 participants recruited from the AMBITION-cm trial. We estimated individual-level exposure to amphotericin B, flucytosine, and fluconazole. Associations between immune biomarkers, pharmacokinetic parameters, and clinical outcomes were evaluated.<h4>Results</h4>An inflammatory cerebrospinal fluid response, characterized by coordination between tumor necrosis factor-α, gra"],"journal":["Open forum infectious diseases"],"pubmed_title":["Relative Contribution of Pharmacokinetics and Immune Signatures to Clinical Outcomes in Patients With HIV-associated Cryptococcal Meningitis."],"pmcid":["PMC12015468"],"funding_grant_id":["NIHR134342","203919/Z/16/Z"],"pubmed_authors":["Kumwenda M","Kugonza F","Masina N","Kukacha C","Jarvis JN","Shah R","Morar T","Chitulo G","Williams D","Ssemusu M","Mnguni T","Mwarumba T","Kiiza D","Tegha G","AMBITION Study Group","Chimang'anga W","Zambasa A","Ndyetukira J","Hafeez S","Ndalama M","Rulaganyang I","Sadiq A","Lipenga B","Muthoga C","Naude J","Mmipi R","Kufa P","Mudzingwa S","Shah RV","Maya C","Lawrence DS","Ponatshego P","Mphande C","Zinyandu T","Ahmadu A","Alice A","Maughan D","Boloko L","Moyo M","Tembo D","Rwomushana I","Namakhwa D","Mhango W","Kyepa H","Mawoko N","Lalloo DG","Chimphambano T","Goodall J","Lechiile K","Davids L","Ngoma D","Okirwoth M","Sturny-Leclere A","Chome N","Sebesho L","Goliath R","Nicholas S","Shey M","Sayed S","Swanepoel L","Rodgers A","Kadzilimbile A","Inyakuwa C","Bookholane H","Akampurira A","Oliphant I","Alanio A","Dromer F","Msumba L","Mwesigye J","Kumwenda E","Gakuru J","Kolamunnage-Dona R","Cresswell F","Singini A","Kazembe M","Rukundo J","Atwine L","Kachitosi T","Gondwe E","Kisembo J","Zambezi J","Kamanga B","Munthali T","Ahimbisibwe C","Tadeo K","Bekiswa A","Emily N","Moosa S","Boyd K","Dziwani E","Milburn J","Hoffman R","Chasweka M","Griffin P","Crede T","Hlungulu S","Mtisi T","Tlhako N","Namujju O","Kajanga C","Kateta S","Nsangi L","Buzaare P","Muyise R","Luggya T","Ndaferankhande J","Hope W","Kossam E","Tsholo K","Moyo C","Gwin M","Mbangiwa T","Mwandumba HC","Lule A","Kariisa S","Niwamanya S","Stambuli A","Stead G","Chiwoko L","Harrison TS","Tukundane A","Gondo S","Chikaonda T","Sarker C","Musubire A","Kwizera R","Seatla K","Mpalali M","Simwinga L","Stott KE","Laker E","Collins M","Makaha E","Banda T"],"additional_accession":[]},"is_claimable":false,"name":"Relative Contribution of Pharmacokinetics and Immune Signatures to Clinical Outcomes in Patients With HIV-associated Cryptococcal Meningitis.","description":"<h4>Background</h4>Host immune responses to HIV-associated cryptococcal meningitis are critical in disease outcome. Their interaction with antifungal drug exposure is poorly understood. This study explored associations between immune biomarkers, antifungal drug exposure, and clinical outcomes in HIV-associated cryptococcal meningitis.<h4>Methods</h4>We analyzed serial plasma and cerebrospinal fluid immune biomarkers from 64 participants recruited from the AMBITION-cm trial. We estimated individual-level exposure to amphotericin B, flucytosine, and fluconazole. Associations between immune biomarkers, pharmacokinetic parameters, and clinical outcomes were evaluated.<h4>Results</h4>An inflammatory cerebrospinal fluid response, characterized by coordination between tumor necrosis factor-α, gra","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2025-07-03T03:04:29.779Z","creation":"2025-07-03T03:04:29.779Z"},"accession":"S-EPMC12015468","cross_references":{"pubmed":["40271162"],"doi":["10.1093/ofid/ofaf190"]}}